ZA985655B - Crystalline macrolides - Google Patents

Crystalline macrolides

Info

Publication number
ZA985655B
ZA985655B ZA985655A ZA985655A ZA985655B ZA 985655 B ZA985655 B ZA 985655B ZA 985655 A ZA985655 A ZA 985655A ZA 985655 A ZA985655 A ZA 985655A ZA 985655 B ZA985655 B ZA 985655B
Authority
ZA
South Africa
Prior art keywords
macrolides
crystalline
crystalline macrolides
Prior art date
Application number
ZA985655A
Other languages
English (en)
Inventor
Cornelia Dosenbach
Maximillian Grassberger
Otto Hartmann
Jean-Paul Mutz
Gerhard Penn
Sabine Pfeffer
Dierk Wieckhusen
Amarylla Horvath
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10815103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA985655(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA985655B publication Critical patent/ZA985655B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA985655A 1997-06-30 1998-06-29 Crystalline macrolides ZA985655B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9713730.1A GB9713730D0 (en) 1997-06-30 1997-06-30 Organic compounds

Publications (1)

Publication Number Publication Date
ZA985655B true ZA985655B (en) 1998-12-30

Family

ID=10815103

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA985655A ZA985655B (en) 1997-06-30 1998-06-29 Crystalline macrolides

Country Status (32)

Country Link
US (1) US6423722B1 (fr)
EP (1) EP0994880B1 (fr)
JP (2) JP3880634B2 (fr)
KR (1) KR100399765B1 (fr)
CN (1) CN1139595C (fr)
AR (1) AR017754A1 (fr)
AT (1) ATE287410T1 (fr)
AU (1) AU739211B2 (fr)
BR (1) BR9810956A (fr)
CA (1) CA2290412C (fr)
CO (1) CO4940463A1 (fr)
CZ (1) CZ297244B6 (fr)
DE (1) DE69828692T2 (fr)
DK (1) DK0994880T3 (fr)
ES (1) ES2236922T3 (fr)
GB (1) GB9713730D0 (fr)
HK (1) HK1028597A1 (fr)
HU (1) HU227755B1 (fr)
ID (1) ID24897A (fr)
IL (1) IL132761A0 (fr)
MY (1) MY118718A (fr)
NO (1) NO312765B1 (fr)
NZ (1) NZ500994A (fr)
PE (1) PE97699A1 (fr)
PL (1) PL192761B1 (fr)
PT (1) PT994880E (fr)
RU (1) RU2219181C2 (fr)
SK (1) SK285665B6 (fr)
TR (1) TR199903189T2 (fr)
TW (1) TW552264B (fr)
WO (1) WO1999001458A1 (fr)
ZA (1) ZA985655B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
GB0125443D0 (en) * 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
US7875630B2 (en) * 2003-09-03 2011-01-25 Glaxo Group Limited Process salts compositions and use
EP1817314A1 (fr) * 2004-12-01 2007-08-15 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Pimecrolimus amorphe non hygroscopique pulverulent
WO2008057511A2 (fr) * 2006-11-06 2008-05-15 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Ascomycine et pimécrolimus ayant des niveaux réduits de desméthylascomycine et de 32-désoxy-32-épichloro-desméthylascomycine respectivement, et leurs procédés de préparation
WO2008073757A1 (fr) * 2006-12-07 2008-06-19 Helsinn Healthcare Sa Formes cristallines et amorphes d'hydrochlorure de palonosétron
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
ES2550634T3 (es) 2009-07-10 2015-11-11 Boston Scientific Scimed, Inc. Uso de nanocristales para un balón de suministro de fármaco
US10080821B2 (en) 2009-07-17 2018-09-25 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
US8889211B2 (en) 2010-09-02 2014-11-18 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
WO2013022458A1 (fr) * 2011-08-05 2013-02-14 Boston Scientific Scimed, Inc. Procédés de conversion d'une substance médicamenteuse amorphe en une forme cristalline
WO2013028208A1 (fr) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Dispositif médical comprenant un revêtement médicamenteux cristallin
WO2014145780A1 (fr) 2013-03-15 2014-09-18 Biosensors International Group, Ltd. Purification de dérivés de rapamycine
EP3178824A1 (fr) 2015-12-08 2017-06-14 Medichem, S.A. Procédé de préparation de pimecrolimus
CA3060330A1 (fr) * 2017-05-01 2018-11-08 Meda Pharma Gmbh & Co. Kg Procede de conversion d'ascomycine brute en pimecrolimus purifie
EP3741367A1 (fr) 2019-05-21 2020-11-25 Premark Pharma GmbH Traitement de maladies oculaires
WO2024209038A1 (fr) 2023-04-06 2024-10-10 Premark Pharma Gmbh Utilisation de pimecrolimus pour le traitement de la sécheresse oculaire chez des patients caractérisés par un score de coloration cornéenne de 4 ou 5 sur l'échelle de classification d'oxford

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51118816A (en) * 1975-04-08 1976-10-19 Meiji Seika Kaisha Ltd A process for stabilizing non-crystalloidal solid
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
CY1306A (en) 1980-10-01 1985-12-06 Glaxo Group Ltd Aminoalkyl furan derivative
JP2728482B2 (ja) * 1989-01-26 1998-03-18 協和醗酵工業株式会社 マクロライド系抗生物質の精製法
WO1991000865A1 (fr) 1989-07-10 1991-01-24 Gema S.A. Nouvelle forme de cephradine stable, procede de production de celle-ci, et produits intermediaires utilises
NZ235991A (en) * 1989-11-09 1993-05-26 Sandoz Ltd Macrolide compounds and pharmaceutical compositions thereof
JPH05505798A (ja) * 1990-03-13 1993-08-26 フアイソンズ・ピーエルシー 免疫抑制マクロ環状化合物
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
EP0480623A1 (fr) * 1990-10-11 1992-04-15 Merck & Co. Inc. Halomacrolides et dérivés ayant une activité immunosuppressive
ES2100291T3 (es) 1991-07-30 1997-06-16 Ajinomoto Kk Cristales de n-(trans-4-isopropilciclohexilcarbonil)-d-fenilalanina y metodos para prepararlos.
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5221740A (en) 1992-01-16 1993-06-22 American Home Products Corporation Oxepane isomers of rapamycin useful as immunosuppressive agents
UA41884C2 (uk) * 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів
US5626757A (en) * 1994-02-22 1997-05-06 Advanced Separation Technologies Inc. Macrocyclic antibiotics as separation agents
AU6900596A (en) * 1995-08-24 1997-03-19 Merck & Co., Inc. Process for the preparation of imidazolyl macrolide immunosuppressants
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds

Also Published As

Publication number Publication date
SK285665B6 (sk) 2007-05-03
US6423722B1 (en) 2002-07-23
DK0994880T3 (da) 2005-05-30
GB9713730D0 (en) 1997-09-03
IL132761A0 (en) 2001-03-19
HUP0003053A2 (hu) 2001-02-28
CZ474099A3 (cs) 2000-04-12
CZ297244B6 (cs) 2006-10-11
JP4504323B2 (ja) 2010-07-14
PT994880E (pt) 2005-06-30
JP3880634B2 (ja) 2007-02-14
DE69828692T2 (de) 2006-01-12
TR199903189T2 (xx) 2000-06-21
AR017754A1 (es) 2001-10-24
NO995909D0 (no) 1999-12-02
JP2006151999A (ja) 2006-06-15
KR20010020423A (ko) 2001-03-15
CA2290412A1 (fr) 1999-01-14
PE97699A1 (es) 1999-10-29
TW552264B (en) 2003-09-11
AU8540998A (en) 1999-01-25
ID24897A (id) 2000-08-31
PL336719A1 (en) 2000-07-03
WO1999001458A1 (fr) 1999-01-14
RU2219181C2 (ru) 2003-12-20
BR9810956A (pt) 2000-09-26
HK1028597A1 (en) 2001-02-23
NZ500994A (en) 2001-08-31
MY118718A (en) 2005-01-31
EP0994880B1 (fr) 2005-01-19
JP2001506279A (ja) 2001-05-15
AU739211B2 (en) 2001-10-04
ATE287410T1 (de) 2005-02-15
HU227755B1 (en) 2012-02-28
NO995909L (no) 1999-12-02
PL192761B1 (pl) 2006-12-29
SK186699A3 (en) 2000-05-16
DE69828692D1 (de) 2005-02-24
CN1261365A (zh) 2000-07-26
KR100399765B1 (ko) 2003-09-29
CO4940463A1 (es) 2000-07-24
CA2290412C (fr) 2009-11-10
NO312765B1 (no) 2002-07-01
ES2236922T3 (es) 2005-07-16
EP0994880A1 (fr) 2000-04-26
HUP0003053A3 (en) 2003-03-28
CN1139595C (zh) 2004-02-25

Similar Documents

Publication Publication Date Title
IL137024A0 (en) Novel macrolides
PL348333A1 (en) Macrolides
PL341209A1 (en) Crystalline teriparatide
EP1147498A4 (fr) Temporisation
AU9277698A (en) 9-amino-3-keto erythromycin derivatives
AU4380797A (en) Macrolides
IL136721A0 (en) Novel erythromycin derivatives
IL132767A0 (en) 9-Oxime erythromycin derivatives
ZA985655B (en) Crystalline macrolides
PL324346A1 (en) Macrolides
IL135519A0 (en) 2-halo-6-0-substituted ketolide derivatives
SG111981A1 (en) Crystalline efavirenz
ZA989835B (en) Erythromycin a derivatives
ZA989830B (en) Erythromycin a derivatives
AU8925398A (en) 3-descladinose 6-o-substituded erythromycin derivatives
AU6932098A (en) Erythromycin derivatives
ZA981572B (en) Erythromycin a derivatives
EP1044985A4 (fr) Derives d'erythromycine
IL132618A0 (en) Crystalline roxifiban
GB9824151D0 (en) Structural elements
GB9724871D0 (en) Crystalline fluoran compound
PL327915A1 (en) Crystalline progestagenes
ZA984488B (en) Multicyclic erythromycin derivatives
GB9700702D0 (en) Erythromycin derivatives
GB2338967B (en) Structural elements